Derivatives of 2-pyridylmethylamine and pharmaceutical composition based on them

 

This invention relates to substituted derivatives of propanolamine formula (I)

and their pharmaceutically acceptable salts, where R1, R2, R3, R4, Z, m and n are specified in paragraph 1 of the claims. The compounds of formula (I) possess hypolipidemic activity and can be used in medicine. 2 S. and 2 C.p. f-crystals, 2 tab.

Description text in facsimile form (see graphic part).

Claims

1. Derivatives of 2-pyridylmethylamine formula I,

where R1denotes phenyl, oxazolyl, isoxazolyl, thiazolyl, while heteroaryl residue may be substituted by phenyl or pyridium, which can also be substituted with halogen or (C1-C8)-alkyl;

R2denotes hydrogen;

R3denotes the residue of a monosaccharide, disaccharide, trisaccharide or tetrasaccharide;

R4denotes hydrogen or fluorine;

Z represents-NH-Co-C16-alkyl-(C=O), -O-Co16-alkyl-(C=O)-, -(C=O)m-C1-C16-alkyl-(C=O)n, amino acid or diaminotoluenes residue or a covalent bond;

m and n equal 0 Il is 1 denotes phenyl, oxazolyl, isoxazolyl, thiazolyl, and the phenyl or heteroaryl residue may be substituted with halogen or (C1-C8) -alkyl, R2denotes hydrogen, R3denotes the residue of a monosaccharide or disaccharide, R4denotes hydrogen or fluorine, Z represents-NH-Co-C16-alkyl-(C=O), -O-Co16-alkyl-(C=O)-, -(C=O)m-C1-C16-alkyl-(C=O)mcovalent bond, n is 0 or 1, m is 0 or 1, and their pharmaceutically acceptable salts.

3. The compounds of formula I under item 1 or 2, characterized in that the1denotes phenyl, thiazolyl, oxazolyl, isoxazolyl, with aromatic or heteroaromatic residue can be substituted by fluorine, chlorine, bromine, or (C1-C8)-alkyl, R2denotes H, R3indicates

R4denotes hydrogen or fluorine, Z represents-NH-C6-C12-alkyl-C=O-, -O-C6-C12-alkyl-C=O-, -(C=O)m-C6-C12-alkyl-(C=O)nn is 0 or 1,

m is 0 or 1, and their pharmaceutically acceptable salts.

4. Pharmaceutical composition, show

 

Same patents:

The invention relates to organic chemistry and can be used in analytical and biological chemistry, applied medicine

The invention relates to pharmaceutical industry and relates to a method of production of a medicinal product antiarthrosis action of chitin

The invention relates to medicine, namely to synthetic biologically active compounds derived class 1 detoxi-1-N - methylaminoethanol and N-greenexpo acid

The invention relates to compounds that are used as medicines, which have antiendotoxin activity, in particular analogs of lipid A

The invention relates to a method of producing aminosaccharides used as chemical reagents and drugs

The invention relates to the field of medicine and relates to pharmaceutical compositions for the treatment of complex and coronary heart disease, myocardial infarction, myocardiodystrophy, rhythm disturbances associated with the use of cardiac glycosides

The invention relates to medicine and relates to pharmaceutical compositions containing a nucleotide analog, mannitol and modifying additive, which is sodium chloride or a polyol suitable for freeze-drying

The invention relates to medicine, namely to medicinal drug for oral administration for treatment of diseases of viral and immune disorders, including HIV-related

The invention relates to new chemical compound, namely the amide glycyrrhizic acid with 5-aminouracil formula I exhibiting anti-HIV activity in cell culture MT-4, with high efficiency by inhibiting the accumulation of virousspecificakih protein P24 (ID50= 55 ág/ml or 52,8 μm), the total viral antigen (ID50= 75 μg/ml or 72,0 μm), which reduces the activity of the reverse transcriptase (reverts) (RT) (ID50= 55 ág/ml or 52,8 μm)

The invention relates to medicine and relates to improved drug with immunomodulatory, immunocorrective, antiparasitic, anti-sclerotic, antiviral, antibacterial, antifungal, anti-inflammatory and anti-tumor activity, comprising a mixture of greenexpo acid and the monosubstituted esters of monosaccharides, and method of its production

The invention relates to a derivative of gemcitabine formula (I), where R1, R2, R3independently selected from hydrogen and C18and C20saturated and monounsaturated acyl groups, provided that R1, R2, R3can't all be hydrogen

The invention relates to derivatives of 3-N-1,2,3-triazolo-[4,5-d]-pyrimidine of the General formula I, in which a represents O or CH2; X is selected from NR1R2, SR1and C1-C7-alkyl; Y is chosen from SR1, NR1R2and C1-C7-alkyl; R1and R2each independently represents N or C1-C7-alkyl, or R1represents C1-C7-alkyl, optionally substituted in the alkyl chain one atom of O or S or one or more halogen, and R2is hydrogen; R3and R4both represent hydrogen or together form a bond; a is COOH, C(O)NH(CH)pCOOH, C(O)N[(CH2)q-COOH]2WITH(ABOUT)NНСН(COOH)(CH2)rCOOH or 5-tetrazolyl, in which p, q and r each independently is 1, 2 or 3, as well as their pharmaceutically acceptable salts or esters

The invention relates to medicine and veterinary medicine, in particular to medicines for external use, and can be used for the treatment of infected superficial and deep wounds, burns, and inflammatory diseases of the skin and mucous membranes

The invention relates to methods for treating diseases caused by hepatitis B virus (also known as HBV and Epstein-Barr (also known as EBV, which include the introduction of an effective amount of one or more of the active compounds disclosed here, or farmatsevticheskii acceptable derivatives or prodrugs of one of these compounds

FIELD: medicine.

SUBSTANCE: the suggested preparation is being cytidine diphosphate choline (CDP-choline) known previously as the preparation to restore cerebral phospholipid structure and for treating mammalians, people among them, subjected to the action of stimulants. Moreover, it is necessary to note that CDP-choline decreases the duration of abstinence symptoms (tremor, convulsions, weakness, emotional instability, nervousness, social reserve) and causes either the decrease or stoppage of alcohol intake.

EFFECT: higher efficiency of therapy.

5 cl, 5 ex

Up!